IBDEI1NI ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27626,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,27626,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,27626,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,27627,0)
 ;;=C91.11^^132^1320^45
 ;;^UTILITY(U,$J,358.3,27627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27627,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,27627,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,27627,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,27628,0)
 ;;=C91.10^^132^1320^46
 ;;^UTILITY(U,$J,358.3,27628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27628,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,27628,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,27628,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,27629,0)
 ;;=C92.11^^132^1320^47
 ;;^UTILITY(U,$J,358.3,27629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27629,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,27629,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,27629,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,27630,0)
 ;;=C92.10^^132^1320^48
 ;;^UTILITY(U,$J,358.3,27630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27630,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,27630,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,27630,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,27631,0)
 ;;=D47.1^^132^1320^49
 ;;^UTILITY(U,$J,358.3,27631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27631,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,27631,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,27631,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,27632,0)
 ;;=C82.69^^132^1320^50
 ;;^UTILITY(U,$J,358.3,27632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27632,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27632,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,27632,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,27633,0)
 ;;=C82.60^^132^1320^51
 ;;^UTILITY(U,$J,358.3,27633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27633,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,27633,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,27633,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,27634,0)
 ;;=D56.2^^132^1320^52
 ;;^UTILITY(U,$J,358.3,27634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27634,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,27634,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,27634,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,27635,0)
 ;;=D75.9^^132^1320^53
 ;;^UTILITY(U,$J,358.3,27635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27635,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,27635,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,27635,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,27636,0)
 ;;=D59.0^^132^1320^56
 ;;^UTILITY(U,$J,358.3,27636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27636,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,27636,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,27636,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,27637,0)
 ;;=D59.2^^132^1320^57
 ;;^UTILITY(U,$J,358.3,27637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27637,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,27637,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,27637,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,27638,0)
 ;;=R59.9^^132^1320^60
 ;;^UTILITY(U,$J,358.3,27638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27638,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
